Natural History Study of Patients With Excess Androgen
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Endocrine, Hematology |
| Therapuetic Areas: | Endocrinology, Hematology |
| Healthy: | No |
| Age Range: | Any - 80 |
| Updated: | 4/6/2019 |
| Start Date: | November 3, 2005 |
This study will evaluate and gather information in patients with genetic causes of too much
androgen (male-like hormone) in order to better understand the effects of too much androgen
and describe problems associated with it. Too much androgen in childhood, if untreated,
results in rapid growth and early puberty with early cessation of growth and short stature in
adulthood. Too much androgen in adulthood may result in infertility, and women may have
excess facial hair, acne and a more male-like appearance. Excess androgen may also affect
mood and behavior and possibly the secretion of other hormones, such as insulin. Two genetic
diseases that result in early childhood androgen excess are congenital adrenal hyperplasia
(CAH) and familial male-limited precocious puberty (FMPP).
Patients with known or suspected CAH due to 21-hydroxylase deficiency, 11- hydroxylase
deficiency, or 3-beta-hydroxysteroid dehydrogenase deficiency and males with known or
suspected FMPP may be eligible for this study. Patients with both classic and non-classic CAH
are eligible, and patients with androgen excess of unknown cause may be eligible.
Participants undergo the following procedures:
- Medical history and physical examination.
- Fasting blood tests for analysis of hormones, blood chemistries including blood sugar
and cardiovascular risk factors such as lipids.
- Oral glucose tolerance test for patients with elevated insulin levels. For this test, a
catheter (plastic tube) is placed in a vein in the patient's arm. The patient drinks a
sugar-containing fluid and blood samples are collected through the catheter at intervals
starting with drinking the solution, and then 30, 60 and 120 minutes after drinking the
solution.
- 24-hour urine collection to measure hormone levels in the urine.
- DNA testing for patients with 21-hydroxylase deficiency to help identify the type of
genetic mutation responsible for the disease.
- X-ray of the left hand to measure bone age in growing children. The x-ray is used to
determine how far into puberty the child is and how much growth potential is left in the
bones.
- A pelvic ultrasound in females and testicular ultrasound in males to evaluate the size
and development of the gonads (ovaries in females and testes in males).
- Cognitive and psychological tests, including an IQ test and evaluation of memory,
achievement and behavior.
- Other tests and evaluations based on medical need.
The schedule for these procedures varies. In a part of the study involving only patients with
CAH, growing children are evaluated twice (once in childhood and once after reaching adult
height), and adults are evaluated once. In another part of the study involving patients with
CAH and FMPP, growing children are seen twice a year, and adults and children who have
reached adult height may be seen annually. Additional visits may be scheduled if medically
indicated. In this part of the study, females are asked to keep a record of their periods
after their first menstrual cycle.
androgen (male-like hormone) in order to better understand the effects of too much androgen
and describe problems associated with it. Too much androgen in childhood, if untreated,
results in rapid growth and early puberty with early cessation of growth and short stature in
adulthood. Too much androgen in adulthood may result in infertility, and women may have
excess facial hair, acne and a more male-like appearance. Excess androgen may also affect
mood and behavior and possibly the secretion of other hormones, such as insulin. Two genetic
diseases that result in early childhood androgen excess are congenital adrenal hyperplasia
(CAH) and familial male-limited precocious puberty (FMPP).
Patients with known or suspected CAH due to 21-hydroxylase deficiency, 11- hydroxylase
deficiency, or 3-beta-hydroxysteroid dehydrogenase deficiency and males with known or
suspected FMPP may be eligible for this study. Patients with both classic and non-classic CAH
are eligible, and patients with androgen excess of unknown cause may be eligible.
Participants undergo the following procedures:
- Medical history and physical examination.
- Fasting blood tests for analysis of hormones, blood chemistries including blood sugar
and cardiovascular risk factors such as lipids.
- Oral glucose tolerance test for patients with elevated insulin levels. For this test, a
catheter (plastic tube) is placed in a vein in the patient's arm. The patient drinks a
sugar-containing fluid and blood samples are collected through the catheter at intervals
starting with drinking the solution, and then 30, 60 and 120 minutes after drinking the
solution.
- 24-hour urine collection to measure hormone levels in the urine.
- DNA testing for patients with 21-hydroxylase deficiency to help identify the type of
genetic mutation responsible for the disease.
- X-ray of the left hand to measure bone age in growing children. The x-ray is used to
determine how far into puberty the child is and how much growth potential is left in the
bones.
- A pelvic ultrasound in females and testicular ultrasound in males to evaluate the size
and development of the gonads (ovaries in females and testes in males).
- Cognitive and psychological tests, including an IQ test and evaluation of memory,
achievement and behavior.
- Other tests and evaluations based on medical need.
The schedule for these procedures varies. In a part of the study involving only patients with
CAH, growing children are evaluated twice (once in childhood and once after reaching adult
height), and adults are evaluated once. In another part of the study involving patients with
CAH and FMPP, growing children are seen twice a year, and adults and children who have
reached adult height may be seen annually. Additional visits may be scheduled if medically
indicated. In this part of the study, females are asked to keep a record of their periods
after their first menstrual cycle.
Androgen excess in childhood results in pseudoprecocious puberty, accelerated childhood
growth with premature epiphyseal fusion, adult short stature, and unknown metabolic and
psychological perturbations. Congenital adrenal hyperplasia (CAH) and familial male-limited
precocious puberty (FMPP) are two genetic diseases that result in early childhood androgen
excess, and CAH due to 21-hydroxylase deficiency is the most common cause of hyperandrogenism
in childhood. This protocol will elucidate a comprehensive phenotypic profile for patients
with CAH and FMPP. Data will be collected in a large cohort of patients regarding growth and
development, hormonal and metabolic factors and psychological characteristics. This protocol
will allow investigators to compare patients with androgen excess of different etiologies,
elucidate androgen-mediated and disease-specific phenotypic characterizations, and allow the
investigators to acquire further knowledge for use in the design of future therapeutic
interventions.
growth with premature epiphyseal fusion, adult short stature, and unknown metabolic and
psychological perturbations. Congenital adrenal hyperplasia (CAH) and familial male-limited
precocious puberty (FMPP) are two genetic diseases that result in early childhood androgen
excess, and CAH due to 21-hydroxylase deficiency is the most common cause of hyperandrogenism
in childhood. This protocol will elucidate a comprehensive phenotypic profile for patients
with CAH and FMPP. Data will be collected in a large cohort of patients regarding growth and
development, hormonal and metabolic factors and psychological characteristics. This protocol
will allow investigators to compare patients with androgen excess of different etiologies,
elucidate androgen-mediated and disease-specific phenotypic characterizations, and allow the
investigators to acquire further knowledge for use in the design of future therapeutic
interventions.
- INCLUSION CRITERIA:
1. Males , ages 0 - 99 with known or suspected FMPP.
2. Patients (males and females, ages 0 - 99) with known (based on hormonal, clinical
and/or genetic testing) CAH due to 21-hydroxylase deficiency, 11-hydroxylase
deficiency, or 3-beta-hydroxysteroid dehydrogenase deficiency. Patients with both
classic and nonclassic patients are eligible.
3. Patients, (males and females, ages 0 - 99 years) with suspected (based on
hormonal, clinical and/or genetic findings) CAH due to 21-hydroxylase deficiency,
11-hydroxylase deficiency, 3-beta-hydroxysteroid dehydrogenase deficiency, or a
rare form of CAH (17-hydroxylase deficiency, steroid acute regulatory protein,
cholesterol side-chain cleavage enzyme deficiency, P450 oxidoreductase
deficiency).
4. Patients with excess androgen of unknown etiology.
5. Relatives of patients with CAH and FMPP.
EXCLUSION CRITERIA:
1. Females with isolated polycystic ovary syndrome. If, following a diagnostic work-up, a
patient is determined to have PCOS as the only cause of her hyperandrogenism; she will
no longer be followed on this protocol.
2. Patients with significant nonendocrine medical conditions.
3. Females who are pregnant at the time of initial enrollment
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
